-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Reiterates Outperform on Keros Therapeutics, Raises Price Target to $27

Benzinga·11/12/2025 16:30:46
Listen to the news
Oppenheimer analyst Andreas Argyrides reiterates Keros Therapeutics (NASDAQ:KROS) with a Outperform and raises the price target from $23 to $27.